TY  - JOUR
AU  - Koerber, Stefan A
AU  - Sprute, Katharina
AU  - Kratochwil, Clemens
AU  - Winter, Erik
AU  - Haefner, Matthias F
AU  - Katayama, Sonja
AU  - Schlampp, Ingmar
AU  - Herfarth, Klaus
AU  - Kopka, Klaus
AU  - Afshar-Oromieh, Ali
AU  - Zschaebitz, Stefanie
AU  - Holland-Letz, Tim
AU  - Choyke, Peter L
AU  - Jaeger, Dirk
AU  - Hohenfellner, Markus
AU  - Haberkorn, Uwe
AU  - Debus, Juergen
AU  - Giesel, Frederik
TI  - Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer.
JO  - European journal of nuclear medicine and molecular imaging
VL  - 48
IS  - 1
SN  - 1619-7089
CY  - Heidelberg [u.a.]
PB  - Springer-Verl.
M1  - DKFZ-2020-01038
SP  - 143-151
PY  - 2021
N1  - 2021 Jan;48(1):143-151
AB  - First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic disease that may be amenable to image-guided radiotherapy. The current study classifies the type and localization of metastases and the clinical outcome of PSMA-PET/CT-guided radiotherapy to selected metastases.Between 2011 and 2019, 86 patients with recurrent, oligometastatic prostate carcinoma were identified by PSMA-PET/CT and were treated with image-guided radiotherapy of their metastases. Sites of relapse were characterized, and the primary endpoint overall survival (OS), biochemical progression-free survival (bPFS), and androgen deprivation therapy (ADT)-free survival were tabulated.In total, 37
LB  - PUB:(DE-HGF)16
C6  - pmid:32405735
DO  - DOI:10.1007/s00259-020-04777-z
UR  - https://inrepo02.dkfz.de/record/154800
ER  -